This is a reference monoclonal antibody to ANGPTL3, designed to mimic evinacumab for research purposes. Evinacumab is a monoclonal antibody that inhibits angiopoietin-like 3 (ANGPTL3), a protein regulating lipid metabolism. By blocking ANGPTL3, it significantly reduces levels of low-density lipoprotein cholesterol (LDL-C), triglycerides, and high-density lipoprotein cholesterol (HDL-C). It is primarily used in the treatment of homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder with extremely high LDL-C levels and increased risk of early cardiovascular disease. Evinacumab is administered intravenously and is effective in patients unresponsive to conventional lipid-lowering therapies like statins, PCSK9 inhibitors, or ezetimibe. Its mechanism enables LDL-C reduction independent of the LDL receptor pathway, benefiting patients with defective or absent LDL receptors. Ongoing research explores its potential in other severe dyslipidemias and broader cardiovascular risk reduction.